A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BllB037 in Subjects with Prodromal or Mild Alzheimer's Disease
What is the purpose of this trial?
This multi-center, double-blind, placebo-controlled study will evaluate the safety and tolerability of multiple doses of BIIB037 in subjects with prodromal or mild Alzheimer's disease. Subjects will be randomized to recieve either one of 3 doses of BIIB037 or placebo. The study period consists of screening, a 12-week treatment period, and an 18-week safety follow-up period.
- Biogen Idec, Inc.
- Last Updated:
- Study HIC#: